Dieter Dorsch

This inventor holds 147 USPTO granted patents and 7 published patent applications, plus 36 CIPO patents and 65 EPO patents, primarily in Pharmaceutical Chemistry (CPC class C07D401-14). Top assignees: Merck Patent Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung, Merck Patent Gesellschaft. Active years: 1989-2026.

USPTO Granted Patents = 147 (Patent Applications = 7)

% Patents Active = 48.3

CIPO Patents = 36 (Patent Applications = 7)

EPO Patents = 65 (Patent Applications = 58)

Average Co-Inventor Count = 4.5

ph-index = 14

Forward Citations = 837(Granted Patents)

Forward Citations (Not Self Cited) = 745(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Darmstadt, DE (1989 - 1998)
Ober-Ramstaddt, DE (2011)
Ober-Ramstadt, DE (1993 - 2024)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

patents

4 out of 121

Merck Patent Gesellschaft

patents

4. 3 out of 100

Merck Patent Gesellschaft MIT Beschraenkter Haftung

patents

5. 2 out of 1,524

Ciba Specialty Chemicals Corporation

patents

6. 1 out of 6,858

Ciba-Geigy Corporation

Years Active: 1989-2026

Loading Chart...

Areas of Expertise:

Indazolyl-Isoxazole Derivatives

Quinolin-2-One Derivatives

Pyridazinone Derivatives

Kinase Inhibitors

Triazolo[4,5-D]Pyrimidine Derivatives

Piperidine Urea Derivatives

Benzonitrile Derivatives

7-Azaindole Derivatives

Macrocycles

Heterocylic Derivatives

Poly(ADP-Ribose)Polymerase

Furo[3,2-B]Pyridin Derivatives

147 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655142 - 4-(imidazo[1,2-a]pyridin-3-yl)-pyrimidine (2026-06-16),

2. 12486260 - Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer (2025-12-02),

3. 11939314 - Quinolin-2-one derivatives (2024-03-26),

4. 11186562 - Quinolin-2-one derivatives (2021-11-30),

5. 11174241 - Quinolin-2-one derivatives (2021-11-16),

6. 10669251 - Quinolin-2-one derivatives (2020-06-02),

7. 10570149 - Tricyclic heterocylic derivatives (2020-02-25),

8. 10570116 - 1,4-dicarbonyl-piperidyl derivatives (2020-02-25),

9. 10179777 - 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives (2019-01-15),

10. 9901577 - Oxoquinazolinyl-butanamide derivatives (2018-02-27),

11. 9861635 - Macrocycles as kinase inhibitors (2018-01-09),

12. 9855268 - Triazolo[4,5-d]pyrimidine derivatives (2018-01-02),

13. 9809598 - Heterocyclyl-butanamide derivatives (2017-11-07),

14. 9770446 - Piperidine urea derivatives (2017-09-26),

15. 9751842 - Phthalazine derivatives (2017-09-05),

Title: Dieter Dorsch: A Remarkable Innovator in Cancer Treatment

Introduction:

Dieter Dorsch, a prolific inventor and researcher hailing from Ober-Ramstadt, Germany, has made significant contributions to the field of cancer treatment. With an impressive number of 144 patents to his name, Dorsch has demonstrated a commitment to advancing medical science through his inventive work. This article will delve into his latest patents, career highlights, notable collaborations, and conclude by acknowledging his invaluable contributions to the field.

Latest Patents:

One of Dorsch's recent groundbreaking inventions is a series of quinolin-2-one derivatives, compounds that act as inhibitors of c-Kit kinase. These compounds have demonstrated potential as effective treatments for cancer. Through his keen insights and meticulous research, Dorsch has discovered a new avenue for combating this debilitating disease. The compounds' formula and meanings are comprehensively detailed in Claim, making them valuable tools in the fight against cancer.

Career Highlights:

Dieter Dorsch's professional journey in the world of innovation began with his association with Merck Patent GmbH, a well-known pharmaceutical company in Germany. Throughout his tenure at Merck, Dorsch played a vital role in driving the company's research and development efforts. His contributions led to numerous breakthroughs, positioning Merck as a key player in cancer treatment and other therapeutic areas.

Collaborations:

Dorsch's exemplary work would not have been possible without the collaboration and support of his esteemed colleagues. Among his notable collaborators are Werner Mederski and Oliver Schadt, individuals who have made significant contributions alongside Dorsch. Together, they have shared their expertise and knowledge, forming a collaborative synergy that has brought about remarkable innovations in the medical field.

Conclusion:

Dieter Dorsch's relentless pursuit of scientific excellence and his unmatched passion for finding solutions to complex medical challenges have established him as a trailblazer in the field of cancer treatment. His latest patents referring to quinolin-2-one derivatives offer promising possibilities for combating this disease, bringing new hope to patients worldwide. Dorsch's career affiliations with prominent pharmaceutical entities such as Merck Patent GmbH and Merck Patent Gesellschaft Mit Beschrankter Haftung highlight his involvement in cutting-edge research. Collaborations with accomplished individuals like Werner Mederski and Oliver Schadt further emphasize the breadth of his professional network. Dieter Dorsch's unwavering dedication to innovation and patentable inventions undoubtedly make him an invaluable contributor to medical science.